Medicine and Dentistry
Inflammatory Bowel Disease
100%
Crohn's Disease
58%
Cohort Analysis
36%
Inflammatory Bowel Disease
35%
Ulcerative Colitis
34%
Microbiome
20%
Diseases
18%
Patient with Inflammatory Bowel Disease
15%
Colitis
15%
Meta-Analysis
14%
Disease Exacerbation
14%
Surgery
14%
Pediatrics
12%
Cohort Effect
8%
Patient with Crohn's Disease
8%
Antibiotics
8%
Clinical Trial
7%
Systematic Review
7%
Bowel Resection
7%
Drug Therapy
7%
Hazard Ratio
7%
Malignant Neoplasm
7%
Prognostication
7%
Maturity Onset Diabetes of the Young
7%
Family History
7%
Lactation
7%
Vermiform Appendix
7%
Tumor Necrosis Factor
7%
Pouchitis
7%
Enteritis
7%
Offspring
7%
Degree Relative
7%
Diagnostic Criterion
7%
Cross-Sectional Imaging
7%
Prevalence
6%
Disease Course
6%
Odds Ratio
5%
Environmental Exposure
5%
Keyphrases
Inflammatory Bowel Disease
49%
Crohn's Disease
12%
Advanced Therapies
8%
American Gastroenterological Association
8%
Risankizumab
8%
Disease Risk
8%
Meta-analysis
7%
Population-based Cohort Study
7%
Epidemiology of Inflammatory Bowel Disease
7%
Risk Pathway
7%
Population-based Study
7%
Cancer Development
7%
Pediatric Onset
7%
Disease Risk Factors
7%
Environmental Modification
7%
Mebendazole
7%
Proteomics
7%
Changing Epidemiology
7%
Green Risk
7%
Changing World
7%
Breastfeeding Duration
7%
Population-based Birth Cohort
7%
Non-associated
7%
Substance Exposure
7%
Offspring Risk
7%
Risk Outcomes
7%
Micro-nano Plastics
7%
Simple Endoscopic Score for Crohn's Disease
7%
Clinical Trials
7%
Race Representation
7%
Gender Representation
7%
Development of Diagnostic Criteria
7%
Moderate to Severe
7%
Upadacitinib
7%
Comparative Efficacy
7%
Vedolizumab
5%
Ustekinumab
5%
Massive Bowel Resection
5%
Pharmacology, Toxicology and Pharmaceutical Science
Inflammatory Bowel Disease
44%
Crohn's Disease
25%
Cohort Study
14%
Risankizumab
12%
Remission
11%
Ulcerative Colitis
10%
Ustekinumab
9%
Vedolizumab
9%
Tumor Necrosis Factor
8%
Tumor Necrosis Factor Inhibitor
8%
Mirikizumab
7%
Upadacitinib
7%
Guselkumab
7%
Adalimumab
7%
Antibiotics
7%
Clinical Trial
7%
Mebendazole
7%
Nanoplastics
7%
Malignant Neoplasm
7%
Colitis
7%
Infliximab
7%
Certolizumab Pegol
6%
Mercaptopurine
5%
Disease
5%